Navigation Links
Vermillion Announces Notice of Allowance for Peripheral Artery Disease (PAD) Patent
Date:8/1/2011

nticipated results or other expectations expressed in such forward-looking statements. Factors that could cause actual results to materially differ include but are not limited to: (1) uncertainty as to Vermillion's ability to protect and promote its proprietary technology; (2) Vermillion's lack of a lengthy track record successfully developing and commercializing diagnostic products; (3) uncertainty as to whether Vermillion will be able to obtain any required regulatory approval of its future diagnostic products; (4) uncertainty of the size of market for its existing diagnostic tests or future diagnostic products, including the risk that its products will not be competitive with products offered by other companies, or that users will not be entitled to receive adequate reimbursement for its products from third party payors such as private insurance companies and government insurance plans; (5) uncertainty that Vermillion will successfully license or otherwise successfully partner with third parties to commercialize its future products; (6) uncertainty whether the trading in Vermillion's stock will become significantly less liquid; and (7) other factors that might be described from time to time in Vermillion's filings with the Securities and Exchange Commission. All information in this press release is as of the date of this report, and Vermillion expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in Vermillion's expectations or any change in events, conditions or circumstances on which any such statement is based, unless required by law.  

This release should be read in conjunction with the consolidated financial statements and notes thereto included in our most recent reports on Form 10-K and Form 10-Q.  Copies are available through the SEC's Electronic Data Gathering Analysis and Retrieval system (EDGAR) at www.sec.gov
'/>"/>

SOURCE Vermillion, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vermillion Announces Joining Russell Microcap® Index
2. Vermillion Announces Notice of Allowance for Alzheimer Patent
3. Vermillion Announces the Appointment of Bruce Huebner to its Board of Directors
4. Vermillion to Host Conference Call to Present Company Update and Review Financial Results for the First Quarter 2011
5. Stephens Initiates Coverage on Vermillion
6. Vermillion Announces Notice of Allowance of Patent for Breast Cancer Biomarkers
7. Vermillion Announces Issuance of European Patent
8. Vermillion to Attend Society of Gynecologic Oncologists Meeting March 15-19
9. Medicare Establishes Reimbursement Coverage for Vermillions OVA1(TM) Test
10. Vermillion Announces Appointment of William C. Wallen, Ph.D. to Board of Directors
11. Vermillion Announces Return of Eric Fung, M.D., Ph.D.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... CAMBRIDGE, Mass. , April 21, 2015 ... clinical data from a multi-arm Phase 1 study of ... data were presented in an oral session by Dr. ... Association for Cancer Research Annual Meeting in ... and tolerability of MM-141 as a monotherapy and in ...
(Date:4/21/2015)... 2015 Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) ... on Thursday, April 23, 4:30 p.m. ET. Participants are ... Investor call information: U.S./ ... toll number: (925) 418-7845 Participant Passcode: 32888538 ... Amirkiai , tina.amirkiai@fleishman.com . Access will ...
(Date:4/21/2015)... Calif. , April 21, 2015 /PRNewswire/ ... provider of advanced cryogenic logistics solutions for ... immunotherapies, stem cells, cell lines, clinical research ... announced that Dr. Mark W. Sawicki ... the 3rd Annual BioLogistics Summit in ...
(Date:4/21/2015)... Mass. , April 21, 2015 /PRNewswire/ ... developing transformative pharmaceutical products for subcutaneous delivery, ... pivotal trial of its investigational proprietary drug ... of edema associated with congestive heart failure. ... scPharmaceuticals is developing a proprietary patch pump.  ...
Breaking Biology Technology:First-in-Human Phase 1 Trial of MM-141 Demonstrates Activity in Biomarker Positive Patients 2First-in-Human Phase 1 Trial of MM-141 Demonstrates Activity in Biomarker Positive Patients 3First-in-Human Phase 1 Trial of MM-141 Demonstrates Activity in Biomarker Positive Patients 4First-in-Human Phase 1 Trial of MM-141 Demonstrates Activity in Biomarker Positive Patients 5Ampio Announces Investor Call on Thursday, April 23, 4:30 p.m. ET 2Cryoport to Present at the 3rd Annual BioLogistics Summit in San Francisco, CA 2Cryoport to Present at the 3rd Annual BioLogistics Summit in San Francisco, CA 3scPharmaceuticals Announces Start of Pivotal Trial for Novel Furosemide Solution for Subcutaneous Delivery 2scPharmaceuticals Announces Start of Pivotal Trial for Novel Furosemide Solution for Subcutaneous Delivery 3
... ET; 8:00 a.m. PT, VANCOUVER and SAN DIEGO, ... a clinical-stage developer of drugs for infectious,diseases, will host ... at 11:00 a.m. ET (8:00 a.m. PT) to discuss ... 2008 and provide an update on,company activities. To participate ...
... on Detroit Area, DETROIT, March 11 ... its new study, Affordable Broadband:,Empowering Communities Across the ... to education, health care and civic,involvement in minority ... Empowerment Council (DEC) that was launched,earlier this year ...
... March 11 Haemonetics,Corporation announced today the appointment ... Chief Marketing Officer. In this position, Mr. Allen,will ... portfolio in addition to his current responsibilities as ... commented, "Pete Allen was an,architect of our strategic ...
Cached Biology Technology:Study Finds Broadband Access Key to Empowerment of Minority Communities 2Haemonetics(R) Appoints Peter Allen as Chief Marketing Officer 2
(Date:4/1/2015)... Apr. 1, 2015  NXT-ID, Inc. (NASDAQ: NXTD ... focused on the growing mobile commerce market, announces the ... wallets is underway to early access pre-order customers. ... usage at retail outlets including Walmart, Target, AT&T, Dunkin, ... Wocket was accepted at all outlets and very easy ...
(Date:3/31/2015)... , March 31, 2015   Guidepoint , ... launch of the Post-Surgical Pain Management TRACKER, part of ... tracking usage trends in the medical device and therapeutics ... to data including treatment volumes, market share, and adoption ... pain associated with joint surgery. The Post-Surgical ...
(Date:3/24/2015)... 24, 2015 Research and Markets ( ... "Global Iris Recognition Market 2015-2019" report to their ... Recognition market to grow at a CAGR of 23.5 ... covers the present scenario and the growth prospects of ... To calculate the market size, the report considers the ...
Breaking Biology News(10 mins):NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2
... the next big innovation in sustainable climate technology? ... for Business Law and Regulation at Case Western Reserve ... do just that. "Technology-induced prizes have a long ... on a Climate Prize Rewarding Energy Innovation to Achieve ...
... ST. AUGUSTINE, TRINIDAD AND TOBAGOFlower color in plants ... carotenoids. Research has found that the ultimate color displayed ... also on other factors, including cell shape, presence of ... role of pH in creating color has allowed plant ...
... Ill. Researchers have identified a protein long known to ... growth. Their study, in the journal Oncogene , is ... accomplishes this feat. "People suggested that Runx3 might be ... it is down-regulated in a lot of breast cancer cell ...
Cached Biology News:CWRU law professor eyes prize-based incentives to generate climate innovation 2Engineering blue-hued flowers 2Team identifies new breast cancer tumor suppressor and how it works 2
... ( Abpromise for all tested ... Synthetic peptide derived from within residues ... MSY2/YBOX2. (Note: the amino acid ... (Peptide available as ab27460 .) ...
Request Info...
Molecular Biology grade. Ideally suited for DNA and RNA separation and recovery. High gel strength. Gelling temp. 36C. Melting temp. 88C. EEO: 0.05-0.13 Resolution 0.2-40 kb; Rnase/Dnase: none detec...
... Signet offers the most comprehensive, ... requirements. We have incorporated unprecedented quality ... capabilities. This includes proven detection chemistries ... to the TechMate protocol. It also ...
Biology Products: